FATE THERAPEUTICS INC
Close on Oct 19, 2026
- Market cap
- $223.94M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 12, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 13, 2026 | Before market open | $2.10M | $-0.25 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 13, 2026 | Before market open | $1.30M | $-0.26 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 26, 2026 | Before market open | $1.40M | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 13, 2025 | Before market open | $1.70M | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 12, 2025 | During market hours | $1.90M | $-0.29 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 13, 2025 | During market hours | $1.60M | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 5, 2025 | During market hours | $1.90M | $-0.44 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 12, 2024 | During market hours | $3.10M | $-0.40 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 13, 2024 | During market hours | $6.80M | $-0.33 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 9, 2024 | During market hours | $1.90M | $-0.47 | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 26, 2024 | During market hours | $1.70M | $-0.45 | – |
Press releases
Announcements Fate Therapeutics filed with the SEC
Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN
Other events · EX-99.1 to Form 8-K
Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates
Results of operations · EX-99.1 to Form 8-K
TRANSFORMING THE LIVES OF PATIENTS LIV ING WITH AUTOIMMUN E DISEASES AND C ANCER Making Cell Therapies
Other events · EX-99.1 to Form 8-K
Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates
Results of operations · EX-99.1 to Form 8-K
Fate Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
Results of operations · EX-99.1 to Form 8-K
Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates
Results of operations · EX-99.1 to Form 8-K
Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Fate Therapeutics Expands Leadership Team with Appointment of Kamal Adawi as Chief Financial Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates
Results of operations · Exit or restructuring costs · EX-99.1 to Form 8-K
Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors
Executive or director change · Charter or bylaw amendment · Shareholder vote results · Regulation FD disclosure · EX-99.1 to Form 8-K
Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates
Results of operations · EX-99.1 to Form 8-K
Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates
Results of operations · EX-99.1 to Form 8-K
Fate Therapeutics Announces Leadership Transition
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates
Results of operations · EX-99.1 to Form 8-K
Fate Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates
Results of operations · EX-99.1 to Form 8-K
Fate Therapeutics Appoints Neely Mozaffarian, MD, PhD, FACR, to its Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
Results of operations · EX-99.1 to Form 8-K
Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
Results of operations · EX-99.1 to Form 8-K
Fate Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates
Results of operations · EX-99.1 to Form 8-K
Fate Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates
Results of operations · EX-99.1 to Form 8-K
Fate Therapeutics Reports First Quarter 2023 Financial Results and Business Updates
Results of operations · EX-99 to Form 8-K
Fate Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
Results of operations · EX-99 to Form 8-K
Fate Therapeutics Announces Termination of Collaboration Agreement with Janssen, Pipeline Prioritization,
Agreement terminated · Exit or restructuring costs · Executive or director change · Other events · EX-99.1 to Form 8-K
Fate Therapeutics Announces Exercise by ONO Pharmaceutical of Option to HER2-targeted CAR T-Cell Product Candidate for Solid Tumors
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Fate Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Operational Progress
Results of operations · EX-99.1 to Form 8-K
Fate Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Operational Progress
Results of operations · EX-99.1 to Form 8-K
Fate Therapeutics Announces Expansion of Solid Tumor Collaboration with ONO Pharmaceutical for Off-the-Shelf, iPSC-derived CAR NK and CAR T-Cell Cancer Immunotherapies
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Fate Therapeutics Reports First Quarter 2022 Financial Results and Highlights Operational Progress
Results of operations · EX-99.1 to Form 8-K
Fate Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Operational Progress
Results of operations · EX-99.1 to Form 8-K
Fate Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Operational Progress
Results of operations · EX-99.1 to Form 8-K